Trusted Resources: News & Meetings
Latest announcements and gatherings
New Type A ERT Candidate on Track for Clinical Trial
Japanese company, JCR Pharmaceuticals, has received an orphan drug designation from the European Commission for their Sanfilippo type A drug candidate JR-441. This orphan designation will enable the further development of JR-441 in the European Union. The company has plans to prepare for a global clinical trial with JR-441 in patients with Sanfilippo type A to start in 2023.
JR-441 is an enzyme replacement therapy (ERT) utilising JCR’s J-Brain Cargo® BBB-penetrating technology. This form of ERT can cross the blood-brain barrier to deliver sulfamidase, the enzyme deficient in Sanfilippo type A, to where it is most needed.
In other ERT-based clinical trials for Sanfilippo, the enzyme has been unable to cross the blood-brain barrier if it is delivered into the bloodstream. Instead, the enzyme has been delivered via direct injection into the fluid surrounding the brain or the spinal canal to target the neurological aspects of the disease.
BookmarkRelated Content
-
CHOP – Lysosomal Storage Disease (LSD) CenterThe Lysosomal Storage Disease Center at ...
-
Paul Orchard, MDDr. Paul Orchard is the Medical Director...
-
An Observational, Prospective, Multicenter, Natural History Study of Patients With Mucopolysaccharidosis Type IIIAMucopolysaccharidosis type IIIA (MPS III...
-
The Beginning of the End of Allogeneic Transplantation for Hurler SyndromeHurler syndrome (mucopolysaccharidosis t...
-
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration With JCR PharmaceuticalsTakeda Pharmaceutical Company Limited an...
-
Gene Therapy May Reverse Hurler Syndrome, a Rare and Severe Illness in KidsGene therapy might soon offer a new opti...
-
The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-A...Nonrandomized studies are usually exclud...
Powered by
